VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AMPHAmphastar Pharmaceuticals, Inc.
$18.33$808M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAMPHEarnings History

AMPH logoAmphastar Pharmaceuticals, Inc. (AMPH) Earnings History

Elite Compounder

14 years of earnings data (2012–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality

TTM Net Income
$79M
● Profitable
TTM EPS (Diluted)
$1.71
Per share, diluted
YoY EPS Growth
-33.7%
Declining
Net Margin
13.6%
After-tax profitability
EPS Growth Rate (CAGR)
1Y-33.7%
3Y+5.3%
5Y+134.5%
10YN/A
Operating Margin19.5%
Gross Margin49.5%
Return on Equity12.9%
Return on Assets6.1%
Record Annual Net Income$160MFY2024
Record Quarterly EPS$0.96Q2 2019
Consecutive Profitable Years7years
Q1 2026
Net Income$6M
EPS (Diluted)$0.14
YoY Growth-33.7%Declining
QoQ Growth-73.7%Declining

Loading earnings history...

Amphastar Pharmaceuticals, Inc. (AMPH) Earnings Overview

As of June 23, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) reported trailing twelve-month net income of $79M, reflecting -33.7% year-over-year growth. The company earned $1.71 per diluted share over the past four quarters, with a net profit margin of 13.6%.

Looking at the long-term picture, AMPH's 5-year EPS compound annual growth rate (CAGR) stands at +134.5%, indicating exceptional earnings growth. The company achieved its highest annual net income of $160M in fiscal 2024.

Amphastar Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 49.5%, operating margin of 19.5%, and net margin of 13.6%. The company continues to generate positive earnings from operations. View revenue history →

Compared to peers including LNTH ($279M net income, 15.2% margin), PCRX ($9M net income, 1.0% margin), PRGO (-$1.82B net income, -33.5% margin), AMPH has room to improve margins relative to the peer group. Compare AMPH vs LNTH →

AMPH Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
AMPH logoAMPHCurrent
$79M$1.7113.6%12.9%-33.7%—
LNTH logoLNTH
$279M$4.2415.2%21.4%-21.8%
PCRX logoPCRX
$9M$0.231.0%1.0%+107.4%
PRGO logoPRGO
-$1.8B$-13.10-33.5%-39.3%-723.2%
AKRO logoAKRO
-$293M$-3.57--39.2%-29.8%
SUPN logoSUPN
-$29M$-0.50-5.4%-3.7%-151.5%
Best in group
Lowest in group

AMPH Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$98M-38.5%$140M$2.0313.6%19.5%
2024$160M+16.0%$205M$3.0621.8%28.1%
2023$138M+50.5%$197M$2.6021.3%30.6%
2022$91M+47.1%$107M$1.7418.3%21.5%
2021$62M+4327.4%$70M$1.2514.2%16.0%
2020$1M-97.1%$11M$0.030.4%3.1%
2019$49M+952.9%$-39,000$0.9815.2%-0.0%
2018-$6M-227.3%-$9M$-0.12-1.9%-2.9%
2017$5M-57.2%$-895,000$0.091.9%-0.4%
2016$11M+477.9%$16M$0.224.1%6.1%
2015-$3M+74.0%-$7M$-0.06-1.1%-2.7%
2014-$11M-190.2%-$18M$-0.25-5.1%-8.5%
2013$12M-34.4%$17M$1.485.2%7.6%
2012$18M-$25M$2.268.9%12.4%

Download Data

Export AMPH earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AMPH — Frequently Asked Questions

Quick answers to the most common questions about buying AMPH stock.

What is AMPH earnings per share (EPS)?

AMPH trailing twelve-month (TTM) diluted EPS is $1.71, reflecting -33.7% year-over-year growth. The 5-year EPS CAGR is +134.5%. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Amphastar Pharmaceuticals, Inc.'s net income?

Amphastar Pharmaceuticals, Inc. (AMPH) trailing twelve-month net income is $79M as of 2025. Earnings declined -33.7% year-over-year. Amphastar Pharmaceuticals, Inc. has been profitable for 7 consecutive years.

Is AMPH profitable?

Yes, AMPH is profitable with a TTM net income of $79M and a net profit margin of +13.6%. Amphastar Pharmaceuticals, Inc. has generated profits for 7 consecutive years.

What is AMPH's earnings growth rate?

AMPH compound annual EPS growth rates (CAGR): 1-Year: -33.7%, 3-Year: +5.3%, 5-Year: +134.5%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are AMPH's profit margins?

Amphastar Pharmaceuticals, Inc. net profit margin is +13.6%, operating margin is +19.5%, and gross margin is +49.5%. Margins are within a typical range for the sector. Return on Equity is +12.9%.

Is AMPH growing earnings?

AMPH earnings are declining — EPS fell -33.7% year-over-year. TTM net income dropped to $79M. This contrasts with the 5-year CAGR of +134.5%.

What was AMPH's best earnings year?

Amphastar Pharmaceuticals, Inc.'s highest annual net income on record is $160M, achieved in fiscal year 2024. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were AMPH's earnings last quarter?

AMPH's most recent reported quarter was Q1 2026. Net income was $6M with diluted EPS of $0.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.

AMPH Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view